Effects of nanoparticle size and gestational age on maternal biodistribution and toxicity of gold nanoparticles in pregnant mice

Toxicology Letters

Volumn 230, Issue 1, 2014, Pages 10-18

  Yang, Hui ^a,b   Du, Libo ^c   Tian, Xin ^a,d   Fan, Zhenlin ^a   Sun, Cuiji ^a   Liu, Yang ^c   Keelan, Jeffrey A ^e   Nie, Guangjun ^a  

^a NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

^b INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^c INSTITUTE OF CHEMISTRY   (China)

^d SOOCHOW UNIVERSITY   (China)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Biodistribution; Gold nanoparticles; Nanotoxicity; Pregnancy; Size effects

Indexed keywords

GOLD NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CIRCULATION TIME; CONTROLLED STUDY; EMPHYSEMA; EXPOSURE; FEMALE; GESTATIONAL AGE; HISTOPATHOLOGY; KIDNEY; LIVER; LUNG; MATERNAL BIODISTRIBUTION; METABOLISM; MORPHOLOGY; MOUSE; NONHUMAN; ORGAN WEIGHT; PARTICLE SIZE; PRIORITY JOURNAL; SPLEEN; SYNTHESIS; TISSUE DISTRIBUTION; TOXICITY; TOXICOLOGY; TRANSMISSION ELECTRON MICROSCOPY;

BIODISTRIBUTION; GOLD NANOPARTICLES; NANOTOXICITY; PREGNANCY; SIZE EFFECTS;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GESTATIONAL AGE; INJECTIONS, INTRAVENOUS; LUNG; METABOLIC CLEARANCE RATE; METAL NANOPARTICLES; MICE; ORGANOGOLD COMPOUNDS; PARTICLE SIZE; PREGNANCY; PULMONARY EMPHYSEMA; RISK ASSESSMENT; TISSUE DISTRIBUTION;

EID: 84906343050     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2014.07.030     Document Type: Article

References (38)

1. Terentyuk G.S., et al. Circulation and distribution of gold nanoparticles and induced alterations of tissue morphology at intravenous particle delivery. J. Biophotonics 2009, 2(5):292-302.
2. Abduljalil K., et al. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin. Pharmacokinet. 2012, 51:365-396.
3. Alkilany A., Murphy C. Toxicity and cellular uptake of gold nanoparticles: what we have learned so far?. J. Nanopart. Res. 2010, 12:2313-2333.
4. Arvizo R.R., et al. Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future. Chem. Soc. Rev. 2012, 41:2943-2970.
5. Bar-Ilan O., et al. Toxicity assessments of multisized gold and silver nanoparticles in zebrafish embryos. Small 2009, 5:1897-1910.
6. Caruthers S.D., et al. Nanotechnological applications in medicine. Curr. Opin. Biotechnol. 2007, 18:26-30.
7. Chen Y., et al. Assessment of the in vivo toxicity of gold nanoparticles. Nanoscale Res. Lett. 2009, 8(4):858-864.
8. Cherukuri P., et al. Targeted hyperthermia using metal nanoparticles. Adv. Drug Deliv. Rev. 2010, 62(3):339-345.
9. Cobley C.M., et al. Targeting gold nanocages to cancer cells for photothermal destruction and drug delivery. Expert Opin. Drug Deliv. 2010, 7(5):577-587.
10. Dawes M., Chowienczyk P.J. Drugs in pregnancy. Pharmacokinetics in pregnancy. Best Pract. Res. Clin. Obstet. Gynaecol. 2001, 15:819-826.
11. De Jong W., et al. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 2008, 29:1912-1919.
12. Di Gioacchino M., et al. Immunotoxicity of nanoparticles. Int. J. Immunopathol. Pharmacol. 2011, 24:65S-71S.
13. Dreaden E.C., El-Sayed M.A., et al. The golden age: gold nanoparticles for biomedicine. Chem. Soc. Rev. 2012, 41:2740-2779.
14. Frederiksen M.C. Physiologic changes in pregnancy and their effect on drug disposition. Semin. Perinatol. 2001, 25:120-123.
15. Frens G. Controlled nucleation for the regulation of the particle size in monodisperse gold suspensions. Nature 1973, 241:20-22.
16. Hainfeld J.F., et al. Gold nanoparticles: a new X-ray contrast agent. Brit. J. Radiol. 2006, 79:248-253.
17. Hillyer J.F., Albrecht R.M. Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles. J. Pharm. Sci. 2001, 90:1927-1936.
18. Holcberg G., et al. New aspects in placental drug transfer. Isr. Med. Assoc. J. 2003, 5(12):873-876.
19. Hutchison J.E., et al. Triphenylphosphine-stabilized gold nanoparticles. Inorg. Synth. 2004, 34:228-232.
20. Jeyabalan A., Conrad K.P. Renal function during normal pregnancy and preeclampsia. Front. Biosci. 2007, 12:2425-2437.
21. Keelan J.A. Nanotoxicology nanoparticles versus the placenta. Nat. Nanotech. 2011, 6:263-264.
22. Khlebtsov N.G., Dykman L.A. Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chem. Soc. Rev. 2011, 40:1647-1671.
23. Lasagna-Reeves C., et al. Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. Biochem. Biophys. Res. Comm. 2010, 393:649-655.
24. Loebstein R., Koren G. Clinical relevance of therapeutic drug monitoring during pregnancy. Ther. Drug Monit. 2002, 24:15-22.
25. Loebstein R., et al. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin. Pharmacokinet. 1997, 33:328-343.
26. Manna A., et al. Optimized photoisomerization on gold nanoparticles capped by unsymmetrical azobenzene disulfides. Chem. Mater. 2003, 15:20-28.
27. Menezes V., et al. Nanoparticulate drug delivery in pregnancy: placental passage and fetal exposure. Curr. Pharm. Biotech. 2011, 12:731-742.
28. Morgan D.J. Drug disposition in mother and foetus. Clin. Exp. Pharmacol. Physiol. 1997, 24:869-873.
29. Nicklin S., Billington W.D. Macrophage activity in mouse pregnancy. J. Reprod. Immunol. 1979, 1:117-126.
30. Pan Y., et al. Size-dependent cytotoxicity of gold nanoparticles. Small 2007, 3:1941-1949.
31. Pissuwan D., Valenzuela S.M., Cortie M.B. Therapeutic possibilities of plasmonically heated gold nanoparticles. Trends Biotechnol. 2006, 24:62-67.
32. Saunders M. Transplacental transport of nanomaterials. Adv. Rev. 2009, 1:671-684.
33. Schmid G. The relevance of shape and size of Au55 clusters. Chem. Soc. Rev. 2008, 37:1909-1930.
34. Semmler-Behnke M., et al. Biodistribution of 1. 4- and 18-nm gold particles in rats. Small 2008, 4:2108-2111.
35. Sonavane G., et al. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf. B Biointerfaces 2008, 66:274-280.
36. Wang J., et al. Nanoparticles for tumor targeted therapies and their pharmacokinetics. Curr. Drug Metab. 2010, 11:129-141.
37. Yang H., et al. Effects of gestational age and surface modification on materno-fetal transfer of nanoparticles in murine pregnancy. Sci. Rep. 2012, 2847. 10.1038/srep00847.
38. Yu S.S., et al. Size- and charge-dependent non-specific uptake of PEGylated nanoparticles by macrophages. Int. J. Nanomed. 2012, 7:799-813.